Second Look Lab — Research Brief: NO–cGMP pathway in ME/CFS & Long COVID
Computational drug-repurposing brief. Three independent screens (genetics, a long COVID ranking, and a literature hidden-link analysis) converge on the NO-sGC-cGMP vascular pathway in ME/CFS and long COVID, and highlight riociguat and nebivolol as untested follow-up candidates to the Charite vericiguat trial. Hypothesis only. Not medical advice. A SHA-256 hash of this PDF (60a68cb498496e31dd527a905fdba8ea3e9c50816c3017f558d990d46358a968) was timestamped with OpenTimestamps on 2026-11-08.
Authors
- Second Look Lab
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-08
- DOI
- https://doi.org/10.5281/zenodo.24078248
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- preprint